Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
21
3
2020
medline:
23
9
2020
entrez:
21
3
2020
Statut:
ppublish
Résumé
The aim of this review is to describe the major steps leading to the immunosuppressive tumor microenvironment and to summarize some of the new immunotherapies that interfere with these mechanisms. Immunotherapy has improved the outcome of relapsed/metastatic head and neck squamous cell carcinoma (HNSCC). However, most patients still do not respond to treatment and median overall survival remains short with a modest rate of long-term survivors. There is a growing awareness that tumor immune-escape is a complex process that involves many redundant mechanisms other than immune check-points. They interfere with the innate immune response, activation of adaptive immune response, homing of effector T cells, their clonal expansion, viability, and efficiency. This abundance of immunosuppressive mechanisms explains the limited results achieved by immune checkpoint inhibitors. Combined treatments targeting different mechanisms of escape are in development to further improve the outcome of patients with HNSCC. Many mechanisms favor tumor immune-escape. Each tumor exploits preferably some of them and the challenge is to understand which are the best targets in each tumor. This knowledge is an important tool to design future combination strategies based on strong biological rationales, which could offer better results than simple empirical combinations.
Identifiants
pubmed: 32195680
doi: 10.1097/CCO.0000000000000623
pii: 00001622-202005000-00006
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
203-209Références
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018; 50:165.
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017; 541:321–330.
Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375:1856–1867.
Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17:956–965.
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401–410.
Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2019; doi:10.1007/s00018-019-03351-7.
doi: 10.1007/s00018-019-03351-7
Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis 2018; 9:115.
Huber V, Camisaschi C, Berzi A, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol 2017; 43:74–89.
Mauge L, Terme M, Tartour E, Helley D. Control of the adaptive immune response by tumor vasculature. Front Oncol 2014; 4:61.
Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014; 26:605–622.
Sukumar M, Kishton RJ, Restifo NP. Metabolic reprograming of antitumor immunity. Curr Opin Immunol 2017; 46:14–22.
Mandal R, Şenbabaoğlu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016; 1:e89829.
Abd Hamid M, Wang RZ, Yao X, et al. Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8+ tumor-infiltrating T lymphocyte responses. Cancer Immunol Res 2019; 7:1293–1306.
Zhu J, Powis de Tenbossche CG, Cané S, et al. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nat Commun 2017; 8:1404.
Wang HC, Chan LP, Cho SF. Targeting the immune microenvironment in the treatment of head and neck squamous cell carcinoma. Front Oncol 2019; 9:1084.
Terry S, Savagner P, Ortiz-Cuaran S, et al. New insights into the role of EMT in tumor immune escape. Mol Oncol 2017; 11:824–846.
Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 2014; 6:1670–1690.
Ming Y, Dechao J, Shuang Q, et al. Synergistic effect of immune checkpoint blockade and antiangiogenesis in cancer treatment. Molecular Cancer 2019; 18: Article number: 60.
Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145–147.
Argiris A, Li S, Savvides P, et al. Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2019; 37:3266–3274.
Yap TA, Papadopoulos KPP, LoRusso P, et al. A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy. J Clin Oncol 2019; 37(15_suppl). doi:10.1200/JCO.2019.37.15_suppl.TPS2652
Harding JJ, Patnaik A, Moreno V, et al. A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): interim safety, efficacy, and pharmacokinetic findings in advanced cancers. J Clin Oncol 37.2019(suppl 8; Abstr 12) doi:10.1200/JCO.2019.37.8_suppl.12
Rischin D, Groenland SL, Lim AML, et al. Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with Pembrolizumab (pembro): preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2019; 30: (suppl_5): v449–v474.
Sullivan RJ, Moschos SJ, Johnson ML, et al. Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy AACR Annual Meeting 2019; abstr CT072.
Citro S, Bellini A, Miccolo C, et al. Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α. Br J Cancer 2019; 120:658–667.
Mesia R, Bossi P, Hansen AR, et al. Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. Eur J Cancer 2019; 123:138–145.
Weed DT, Zilio S, Reis IN, et al. The reversal of immune exclusion mediated by tadalafil and an antitumor vaccine also induces PDL1 upregulation in recurrent head and neck squamous cell carcinoma: interim analysis of a phase I clinical trial. Front. Immunol 2019; 10:1206.
Cohen EEW, Harrington KJ, Hong DS, et al. A phase 1b/2 study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic HNSCC. Ann Oncol 2018; 29: (suppl_8): viii372–viii399.
Kumar AT, Knops A, Swendseid B, et al. (2019). Prognostic significance of tumor-associated macrophages content in head and neck squamous cell carcinoma: a meta-analysis. Front Oncol 9:656.
Georgoudaki AM, Prokopec KE, Boura VF, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep 2016; 15:2000–2011.
Taylor MH, Rasco DW, Brose MS, et al. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck. Am Soc Clin Oncol 2018; 36: (Suppl. 15): 6016.
Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 2018; 33:463–479.e10.
van Helvert S, Storm C, Friedl P. Mechanoreciprocity in cell migration. Nat Cell Biol 2018; 20:8–20.
Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 2011; 4:165–178.
Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003; 26:44–48.
Liu T, Zhou L, Li D, et al. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol 2019; 7:60.
Fayette J, Lefebvre G, Posner MR, et al. Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma. Ann Oncol 2018; 29: (suppl_8): viii372–viii399.
Pang X, Tang YL, Liang XH. Transforming growth factor-β signaling in head and neck squamous cell carcinoma: insights into cellular responses. Oncol Lett 2018; 16:4799–4806.
Strauss J, Jason Redman M, Madan RA, et al. Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers. J Clin Oncol 2018; 36: (15_suppl): 3007–13007.
Cho BC, Daste A, Ravaud A, et al. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: results from a phase 1 cohort. Ann Oncol 2018; 29: (suppl_8): viii372–viii399.
Mitchell TC, Hamid O, Smith DC, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter open-label phase I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol 2018; JCO2018789602[Epub ahead of print].
Cohen EEW, Rischin D, Pfister DG, et al. A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669. J Clin Oncol 2018; 36:TPS6090doi: 10.1200/ICO.2018.36.15_suppl.TPS6090.
doi: 10.1200/ico.2018.36.15_suppl.tps6090
Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol 2019; 10:379.